Skip to main content

Table 1 Yerelon cohort patient who initiated antiretroviral study participants baseline characteristics

From: Immunovirological discordance among female sex workers who start antiretroviral therapy in Burkina Faso

Variable at ART initiation All Patients (n = 123)
n (%)
Patients with HIV-1 RNA suppressed at 12 months on ART
(VL < 1000 copies/mL)
(n = 105)
n (%)
Immunologic responder at 12 months on ART
(CD4 + T cell recovery ≥ 100 cells)
(n = 86)
n (%)
Patients with immunovirological discordance at 12 months
(n = 25)
n (%)
Age: median (IQR) years 33.00 (29.00–39.17) 33.02 (30.01–39.02) 32.93 (28.5–38.80) 33.00 (31.00–39.23)
 < 30 31 (25.20) 25 (23.81) 23 (26.74) 4 (16.00)
 30–39 65 (52.85) 58 (55.24) 46 (53.49) 15 (60.00)
 ≥ 40 27 (21.95) 22 (20.95) 17 (19.77) 6 (24.00)
Education level     
 None 52 (42.28) 45 (42.86) 38 (44.19) 9 (36.00)
 Primary school 36 (29.27) 31 (29.52) 23 (26.74) 11 (44.)
 Secondary school 35 (28.45 29 (27.62) 25 (29.07) 5 (20.00)
Marital status (couple life)     
 Yes 29 (23.58) 23 (21.90) 21 (24.42) 4 (16.00)
 No 94 (76.42) 82 (78.10) 65 (75.58) 21 (8400)
WHO clinical stage     
 1 17 (13.82) 13 (12.38) 12 (13.95) 3 (12.00)
 2 42 (34.15) 35 (33.33) 29 (33.72) 8 (32.00)
 3 and 4 64 (52.03) 57 (54.29) 45 (52.33) 14 (56.00)
Body mass index: median (IQR) 20.60 (18.55–22.72) 20.58 (18.13–22.55) 20.38 (18.24–22.37) 20.76 (18.55–23.51)
 < 18,5 29 (23.58) 28 (26.67) 23 (26.74) 6 (24.00)
 18,5–25 83 (67.48) 67 (63.81) 57 (66.28) 15 (60.00)
 > 25 11 (8.94) 10 (9.52) 6 (6.98) 4 (16.00)
CD4 + T cell count at ART initiation:
Median (IQR)
147 (79–200) 139 (74–200) 136 (75–192) 238 (100–384)
 < 200 90 (73.17) 77 (73.33) 70 (81.40) 11 (44.00)
 200–349 23 (18.70) 19 (18.10) 14 (16.28) 7 (28.00)
 350 -500 10 (8.13) 9 (8.57) 2 (2.33) 7 (28.00)
HIV-1 Viral load (log 10copies/ml): median (IQR) (n = 52) 5.20 (4.82–5.52) 5.26 (4.85–5.58) 5.18 (4.82–5.54) 5.43 (5.28–5.65)
 < 3 log10 2 (3.85) 2 (4.17) 2 (4.76) -
 3–5 log10 16 (30.77) 13 (27.08) 13 (30.95) 1 (12.50)
 > 5log10 34 (65.38) 33 (68.75) 27 (64.29) 7 (87.50)
ART NNRTIs initiated     
 Nevirapine 38 (30.89) 30 (28.57) 28 (32.56) 5 (20.00)
 Efavirenz 83 (67.48) 73 (69.52) 56 (65.12) 20 (80.00)
 Protease inibitor 2 (1.63) 2 (1.90) 2 (2.33)  
ART NRTIs initiated     
 Tenofovir 18 (14.63) 15 (14.29) 11 (12.79) 6 (24.00)
 Zidovudine 73 (59.35) 64 (60.95) 49 (56.98) 17 (68.00)
 Stavudine 32 (26.02) 26 (24.76) 26 (30.23) 2 (8.00)
ART Adherence: median (IQR) 97.00 (92.5–99.40 97.00 (93.5–99.65) 97.00 (92.00–99.40) 96.40 (95.30–100)
 < 95% 45 (36.59) 37 (35.24) 35 (40.70) 6 (24)
 ≥ 95% 78 (63.41) 68 (64.76) 51 (59.30) 19 (76)
  1. ART antiretroviral therapy, IQR interquartile range, NNRTIs non-nucleoside reverse transcriptase inhibitors, NRTIs nucleoside/nucleotide reverse transcriptase inhibitors